Sweden· SE-20180604000041
GIAPREZA 2,5 mg/ml Koncentrat till infusionsvätska, lösning
A medicinal product containing angiotensin ii, registered in Sweden by PAION Pharma GmbH.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Angiotensin Ii
- Manufacturer
- PAION Pharma GmbH
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20180604000041
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Angiotensin ii in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandGiaprezaPAION Pharma GmbH
- NorwayGiaprezaPAION Pharma GmbH
- United StatesANGIOTENSIN IIGland Pharma Limited
- FranceGIAPREZA 2,5 mg/ml, solution à diluer pour perfusionPAION PHARMA (ALLEMAGNE)
- United KingdomGiapreza 2.5mg/1ml concentrate for solution for infusion vialsPAION Pharma GmbH
- SpainGIAPREZA 2,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONPaion Pharma Gmbh
- NetherlandsGiapreza 2,5 mg/ml concentraat voor oplossing voor infusiePaion Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Giapreza
- Liechtenstein · Giapreza
- Norway · Giapreza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc0a6879-90e6-4ac6-952f-fdff35b36e02 GET /v1/drugs/dc0a6879-90e6-4ac6-952f-fdff35b36e02?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EPAR",
"EMA",
"Dispensbeslut"
],
"se_npl_id": "20180604000041",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20180604000041",
"product_doc_link": "https://www.ema.europa.eu/sv/documents/product-information/giapreza-epar-product-information_sv.pdf"
}See everything about angiotensin ii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.